Eagle Capital Management, an investment management company, released its first quarter 2026 investor letter. A copy of the letter is available to download here. The letter notes that individual stocks and subsectors are now more reactive to sentiments, reducing market efficiency but creating opportunities to add value. Over the last decade, multi-asset managers, or pods, have grown significantly, operating with leverage, tight risk controls, and quickly cutting losers, often relying on earnings momentum. Growth managers have outperformed value managers, attracting flows; retail investors increasingly chase momentum, reducing overall diversity and amplifying momentum’s influence. It’s more valuable to find controversial or underexplored assets early and benefit as earnings grow. Eagle has capitalized on this trend, expecting continued opportunities. Investments should consider probabilities, building portfolios for various outcomes rather than betting on one, which allows for compound growth. The Strategy is generating strong long-term absolute returns. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Eagle Capital Management highlighted Danaher Corporation (NYSE:DHR) as a newly added position. Danaher Corporation (NYSE:DHR) is a healthcare and life science tools company that operates through Biotechnology, Life Sciences, and Diagnostics segments. On May 20, 2026, Danaher Corporation (NYSE:DHR) closed at $171.12 per share. One-month return of Danaher Corporation (NYSE:DHR) was -4.17%, and its shares lost 8.73% over the past 52 weeks. Danaher Corporation (NYSE:DHR) has a market capitalization of $118.23 billion.
Eagle Capital Management stated the following regarding Danaher Corporation (NYSE:DHR) in its Q1 2026 investor letter:
“We’ve built a position in Danaher Corporation (NYSE:DHR), a leading life sciences company. Danaher sells a broad mix of consumables and tooling that are mission-critical to biological R&D, diagnostic testing, and biopharma drug production. It has high market share, differentiated technology, strong management, and good growth prospects.
Over the last several years, Covid-related revenue disappeared, the biotech end-market boomed and then crashed, China slowed, and NIH funding was cut. As a result, this historically stable grower has been anything but stable or growing. It’s now trading at a depressed multiple on depressed earnings. With lower-quality earnings flushed out of the base and other parts running below trend, we expect improving, and possibly even above trend, growth over the coming years. Moreover, one of the most exciting areas of exploration for AI technology is in biopharma research. This has the potential to be a medium- to long-term accelerant for Danaher’s business. We expect EPS growth in the mid-teens.”
Danaher Corporation (NYSE:DHR) ranks 24 on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 125 hedge fund portfolios held Danaher Corporation (NYSE:DHR) at the end of the fourth quarter, up from 117 in the previous quarter. While we acknowledge the risk and potential of Danaher Corporation (NYSE:DHR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Danaher Corporation (NYSE:DHR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Danaher Corporation (NYSE:DHR) and shared billionaire Steve Cohen’s large-cap stock picks with highest upside potential. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
